PODKhODY K TERAPII REFRAKTERNYKh FORM RASSEYaNNOGO SKLEROZA U DETEY


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Currently, number of drugs for the traditional long-term therapy for multiple sclerosis (MS) in adults is registered. Published data from international retrospective studies indicate a good tolerability and safety of interferon-β in children and adolescents with MS. But in childhood, pernicious course of MS often occurs, which is characterized by not only resistance to corticosteroids, but also to immunomodulatory drugs. There is need for a detailed analysis of the risks and benefits of alternative ways to treat MS, when the 1st and sometimes 2nd lines drugs are ineffective. In these settings, one of the most promising directions in MS therapy in children is the use of cellular technology and immunosuppressive drugs in high doses for the achievement of long-term remission of MS.

Texto integral

Acesso é fechado

Bibliografia

  1. Duquette P., Murray T. J., Pleines J. et al. Multiple sclerosis in childhood: clinical profile in 125 patients. J. Pediat. 1987;111(3):359-63.
  2. Ghezzi A., Deplano V., Faroni J., et al. Multiple sclerosis in childhood: clinical features of 149 cases. Multiple Sclerosis. 1997;3(1):43-6.
  3. Бембеева Р.Ц. Демиелинизирующие заболевания детского возраста: стратегия диагностики и лечения. Дисс. Докт. мед. наук. М., 2006.
  4. Derfuss T., Linington C., Hohlfeld R., Meinl E. Axo-glial antigens as targets in multiple sclerosis: implications for axonal and grey matter injury. J. of Molecular Med. 2010;88(8):753-61.
  5. Krupp L.B., Banwell B., Tenembaum S. International Pediatric MS Study Group, Consensus definitions proposed for pediatric multiple sclerosis and related disorders. Neurology. 2007;6 (16):7-12.
  6. Krupp L.B., Tardieu M., Amato M. P. et al. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Multiple Sclerosis J. 2013;19(10):1261-67.
  7. Kornek B. Evaluation of the 2010 McDonald multiple sclerosis criteria in children with a clinically isolated syndrome. Mult. Scler. 2012;18(12):1768-74.
  8. Polman C.H., Reingold S.C., Banwell B., Polman C.H. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Annals of Neurology. 2011;69(2):292-302.
  9. Duquett P., Murray T.I., Pleines I., et al. Multiple sclerosis in childhood: clinical profile in 125 patients. J. Pediat. 1987;111:359-63.
  10. Ghezzi А., Depiano V., Faroni J., et al. Multiple sclerosis in childhood: Clinical features of 149 cases. Mult. Scler. 1997;3:43-6.
  11. Евтушенко С.К., Москаленко М.А. Тяжелые прогрессирующие формы рассеянного склероза у детей. Международный неврол. журнал. 2012;5(51).
  12. Pinhas-Hamiel O., Barak Y., Siev-Ner I., et al. Juvenile multiple sclerosis: Clinical features and prognostic characteristics. J. Pediatr. 1998;132:735-37.
  13. Pohl D., Waubant E., Banwell B., et al. International Pediatric MS Study Group. Treatment of pediatric multiple sclerosis and variants. Neurology. 2007;68(16):54-65.
  14. Banwell B., Reder A. T., Krupp L., et al. Safety and tolerability of interferon beta 1-b in pediatric multiple sclerosis. Neurology. 2006; 66:472-76.
  15. Kappos L., Traboulsee A., Constantinescu C., et al. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology. 2006;67(6):944-53.
  16. Joaquin A. Pena and Timothy E. Lotze. Pediatric Multiple Sclerosis: Current Concepts and Consensus Definitions. Autoimmune Diseases. 2013;Article SD 673947:12.
  17. Chitnis T., Tenembaum S., Banwell B., et al., Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosis. Multiple Sclerosis. 2012;18(1):116-27.
  18. Yeh E.A., Weinstock-Guttman B. Moving on to second-line therapies in pediatric MS: immunosuppression with cyclophosphamide. Neurology. 2009;72 2064-65.
  19. Castillo-Trivino T., Mowry E.M., Gajofatto A., et al. Switching multiple sclerosis with breakthrough disease to second-line therapy. PLoS One. 2011;6:e16664.
  20. Yeh A. Current therapeutic options in pediatric multiple sclerosis. Current Treatment Options in Neurology. 2011;13(6):544-59.
  21. Makhani N., Gorman M.P., Branson H.M., et al. Cyclophosphamide therapy in pediatric multiple sclerosis. Neurology. 2009;72:2076-82.
  22. Greco R. Allogenic hematopoietic stem cell transplantation in refractory neuromyelitis optica spectrum disorders. Bone Marrow Transplant. 2012;47:228-29.
  23. Hamerschlak N. Brazilian experience with two conditioning regimens in patients with multiple sclerosis: BEAM/horse ATG and CY/rabbit ATG. Bone Marrow Transplantation. 2009; 45:239-48.
  24. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurol. 1983;33:1444-52.
  25. Lavorgna L. Clinical and magnetic resonance imaging predictors of disease progression in multiple sclerosis: a nine-year follow-up study. Mult. Scler. 2013;(электронная публикация).
  26. Burt R.K., Loh Y., Cohen B., et al. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study Lancet Neurol. 2009;8(3):244-53.
  27. Schneider-Hohendorf T., Stenner M.P., Weidenfeller C., et al. Regulatory T cells exhibit enhanced migratory characteristics, a feature impaired in patients with multiple sclerosis. Eur. J. Immunol. 2010;40(12):3581-90.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2014

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies